We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Sekisui Diagnostics

Download Mobile App




Post-Treatment Prostate Cancer Outcomes Predicted by MRI

By MedImaging staff writers
Posted on 22 Apr 2008
Findings of a magnetic resonance imaging (MRI) study in patients about to undergo radiation therapy for prostate cancer can help forecast the likelihood that the cancer will recur and metastasize post-treatment.

"This is the first study to show that MRI detection and measurement of the spread of prostate cancer outside the capsule of the prostate is an important factor in determining outcome for men scheduled to undergo radiation therapy,” said study co-author Fergus V. More...
Coakley, M.D., professor of radiology and urology, vice chair for clinical services and section chief of abdominal imaging in the department of radiology at the University of California, San Francisco (UCSF; USA).

When diagnosed and treated early, the five-year survival rate for patients with prostate cancer is nearly 100%. However, once the cancer spreads or recurs beyond the prostate, the chance of survival decreases considerably. One common treatment for prostate cancer is external beam radiation therapy. Dr. Coakley and colleagues tried to determine if MRI results prior to radiation therapy were an indicator of potential recurrence and spread.

The researchers retrospectively reviewed the MR images of 80 men with prostate cancer who had undergone MRI of the prostate before external beam radiation therapy. Details of tumor characteristics, treatment, and outcome were recorded. Utilizing a Cox regression analysis (a technique that correlates the relationship between survival of a patient and several contributing variables), the researchers determined that the presence and level of extracapsular extension (spread of cancer beyond the membrane that surrounds the prostate gland) seen on the pre-treatment MR images was a significant predictor of post-treatment recurrence and spread. Specifically, patients with extracapsular extension greater than 5 mm were more likely to experience recurrence and metastasis of their cancers.

The study was published in the April 2008 issue of the journal Radiology.


Related Links:
University of California, San Francisco

Gold Member
Blood Gas Analyzer
i-Check200
Radiology Monitor
MDNC-6121 Barco Nio Color 5.8MP
Surgical System
Stealth AXiS
Surgical Dressing
ALLEVYN Ag+ SURGICAL
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Artificial Intelligence

view channel
Image: Clinical LLM Performance Improves by >300% When Provided with High-Quality Real-World Evidence in New Precision Medicine Benchmark (Photo courtesy of Atropos Health)

New Benchmark Highlights Evidence Gaps in AI Responses to Clinical Questions

Many clinical decisions still rely on limited evidence, while most artificial intelligence benchmarks overlook the patient context that shapes real-world care. General large language models can also struggle... Read more

Point of Care

view channel
Image Credit: 123RF

Continuous Glucose Monitoring Identifies Cardiometabolic Risk in Adults Without Diabetes

Dysglycemia—abnormal blood glucose regulation—can fluctuate throughout the day and often escape conventional screening. Clinicians typically rely on fasting plasma glucose and hemoglobin A1c, which offer... Read more

Business

view channel
Image: LigaSure RAS Maryland, designed for the Valleylab FT10 platform on Hugo RAS, seals and cuts vessels, tissue, and lymphatics up to 7 mm in diameter (Photo courtesy of Medtronic)

Medtronic Receives FDA Clearance for Vessel-Sealing Instrument for Robotic Surgery

As robotic-assisted surgery expands across U.S. hospitals, teams increasingly seek energy instruments with the familiarity and performance of tools used in open and laparoscopic procedures.... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.